Monte Rosa Therapeutics Inc
NASDAQ:GLUE
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
200.3m USD | -0.1 | |
US |
Abbvie Inc
NYSE:ABBV
|
277.6B USD | 20.2 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
163.2B USD | 30.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.4B USD | 25.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.5B USD | 25.3 | ||
AU |
CSL Ltd
ASX:CSL
|
135.7B AUD | 27.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 11.3 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
63.1B USD | -10.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.8B USD | 17.4 | ||
KR |
Celltrion Inc
KRX:068270
|
37.3T KRW | 79.8 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.